Tag Archives: Dexcom

Novartis Terminates Ph3 Pelacarsen Studies; AZ Partners with insitro; Dexcom Publishes CONNECT RCT Results; Pfizer China-Based QM Berobenatide Obesity Study; Modular Medical Digital Learning Tool; Medtronic Finalizes MiniMed Separation; Atrogi Oral GRK2-Biased ß2-Adrenergic Modulator Data

A series of cardiometabolic-related news items has been observed from Novartis, AstraZeneca, Dexcom, Pfizer, Modular Medical, MiniMed, and Atrogi AB. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

EASD 2026 Winners/Not Winners Analysis: Who Came Out on Top… and Who Didn’t?

Following EASD 2026 (Sep 28-Oct 2; Milan, Italy), FENIX has conducted a winners/not winners analysis, assessing which companies gained further momentum from the conference, remained static, or trended in the wrong direction. Spoiler alert: Lilly clearly came out on top, with EloraTZP setting a new efficacy benchmark for what may be achievable with an amylin + incretin combination. However, winning is not a zero-sum game…

This content is for Read Less members only.
Already a member? Log in here

EASD 2026 Key Press Releases (September 29)

On the second day of EASD 2026, seven key news items were observed from Novo/Hengrui, Lilly, Caspian Therapeutics, Merck/Cyprumed GmbH, and Oura. Below, FENIX provides context and analysis for the announcements.

This content is for Read Less members only.
Already a member? Log in here

EASD 2026 Key Press Releases (September 28)

On the first day of EASD 2026, six key news items were observed from Roche, Tandem Diabetes Care, Dexcom, Lilly, MindRank, and DreaMed Diabetes. Below, FENIX provides context and analysis for the announcements.

This content is for Read Less members only.
Already a member? Log in here

Ascendis/Novo Terminate QM Sema Agreement; Novo Cagrisema Switch Study; Dexcom Appoints COO; Arrowhead ARO-DIMER-PA Data; Elvinix/Zealand ZP3022 Licensing Agreement; Lilly Terminates Ph1 Obesity Asset; Medtronic Expands Separation from MiniMed; Tracky Launches 16-Day CGM in India

A series of cardiometabolic-related news items has been observed from Ascendis Pharma, Novo, Dexcom, Arrowhead Pharmaceuticals, Elvinix, Lilly, MiniMed, and Tracky. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Dexcom Q2 ’26 Earnings; Novo Ziltivekimab CVOT Miss; CSPC Initiates China-Based QM Dual Agonist Study

Three cardiometabolic-related news items have been observed: Dexcom hosted its Q2 ’26 earnings call (view press release; view slides); Novo’s Ph3 ZEUS trial evaluating ziltivekimab missed the primary CV endpoint (view press release); and CSPC initiated a Ph1 study evaluating its QM GLP-1/GIP dual agonist (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

AZ Q2 ’26 Earnings; Ex-Dexcom Executive Joins Luna Diabetes; Ascletis Preclinical Tri-Agonist Data; Ionis Pediatric Olezarsen Study; Lexicon Ph3 Sota Study; Veru Ph2b Enobosarm Study

A series of cardiometabolic-related news items has been observed from AstraZeneca, Luna Diabetes, Ascletis Pharma, Ionis Pharmaceuticals, Lexicon Pharmaceuticals, and Veru. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

D&D and Pfizer Expand Research Agreement; Dexcom G7 15-Day Health Canada Clearance; Insulet Partners with Calm

Three cardiometabolic-related news items have been observed: D&D Pharmatech extended its oral obesity research agreement with Pfizer (view article), Dexcom received clearance of its G7 15-Day CGM in Canada (view press release), and Insulet partnered with Calm to provide well-being resources for diabetes management (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

ADA 2026 Winners/Not Winners Analysis: Who Came Out on Top… and Who Didn’t?

Following ADA 2026 (June 5-8; New Orleans, LA), FENIX conducted a winners/not winners analysis, identifying the companies that came out on top, remained static, or trended in the wrong direction. As a glimpse into the analysis, Lilly (unsurprisingly) clearly came out on top, with the retatrutide pivotal data session filling the room beyond capacity. The ADA organization seemingly had the most negative outcome following the controversy around Steven Kahn’s removal from the event.

This content is for Read Less members only.
Already a member? Log in here